1. Home
  2. TALO vs LQDA Comparison

TALO vs LQDA Comparison

Compare TALO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talos Energy Inc.

TALO

Talos Energy Inc.

HOLD

Current Price

$11.49

Market Cap

1.8B

Sector

Energy

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$33.47

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALO
LQDA
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
TALO
LQDA
Price
$11.49
$33.47
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$14.30
$37.40
AVG Volume (30 Days)
2.0M
1.7M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,872,554,000.00
$69,216,000.00
Revenue This Year
N/A
$904.79
Revenue Next Year
N/A
$188.25
P/E Ratio
N/A
N/A
Revenue Growth
0.06
343.41
52 Week Low
$6.23
$10.37
52 Week High
$12.20
$35.54

Technical Indicators

Market Signals
Indicator
TALO
LQDA
Relative Strength Index (RSI) 57.53 62.18
Support Level $11.55 $32.11
Resistance Level $11.96 $35.54
Average True Range (ATR) 0.39 1.60
MACD -0.04 -0.11
Stochastic Oscillator 47.45 72.94

Price Performance

Historical Comparison
TALO
LQDA

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: